Breakthrough in Blood: Cécile Denis and INSERM Team Develop Nanobody Therapy for Type 1 VWD
Cécile Denis, director of research at INSERM, shared a post on LinkedIn:
”The result of an almost 10-year journey: a bispecific nanobody bridging von Willebrand factor to albumin in order to prolong the half-life of VWF and increasing its plasma levels. A potential treatment for patients with decreased VWF levels (Type 1 VWD).
We should not forget that Von Willebrand disease remains largely underestimated and therefore untreated, especially in type 1 patients.
Thank you Ivan Peyron, Caterina Casari, Geneviève McCluskey, Stéphanie Roullet, Vincent Licari, Emilie BOCQUET, Claire Auditeau, Melanie Daniel, sophie susen, Olivier Christophe, Peter Lenting, HITh lab Inserm, INSERM, ANR Agence nationale de la recherche.”
Read the full study here.
Title: A bispecific nanobody for the treatment of von Willebrand disease type 1
Authors: Ivan Peyron, Caterina Casari, Genevieve McCluskey, Stéphanie Roullet, Vincent N Licari, Emilie Bocquet, Claire Auditeau, Melanie Y Daniel, Sophie Susen, Olivier D. Christophe, Peter J Lenting, Cécile V. Denis
Stay updated with Hemostasis Today.
-
Dec 11, 2025, 03:36Susan Galbraith on AstraZeneca’s Grand Presence at ASH25
-
Dec 10, 2025, 17:22In the Fight for Hematology: Adetokunbo O’s Reflections from ASH25
-
Dec 10, 2025, 17:11Driving Innovation in Rare Blood Disorders: Jeff Schaffnit’s ASH 2025 Perspective
-
Dec 10, 2025, 16:37Arthur Allen – The New President-Elect of the Anticoagulation Forum Board of Directors
-
Dec 10, 2025, 16:29Matthew D Neal: An Oasis in the Platelet Desert?
-
Dec 10, 2025, 16:14Yashpal Singh Rawat: Fortis Memorial Research Institute Made Its Positive Mark at ASH
-
Dec 10, 2025, 14:57Elvira Grandone Announces the 1st ThrombUS+ Data Challenge
-
Dec 10, 2025, 14:18Love Preet Kalra on A Paradigm Shift in ICH
-
Dec 10, 2025, 13:37Aakanksha A: A Highlight of the Week Was Presenting Our ASH Poster